Showing results (261-270 of 269) with videos related to

Sort By:
Pageof 27
You have reached the last page of results.This site can display upto 269 results.
Critical Care Medicine|February 13, 2019
Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)Richard S Hotchkiss, Elizabeth Colston, Sachin Yende, et al.
JAMA Network Open|June 11, 2026
Remote Monitoring Approaches to Reduce Readmissions After Infection and Sepsis: A Randomized Clinical TrialSachin Yende, Victor B Talisa, Kristin Mayes, et al.
Journal of Biotechnology|September 16, 1999
Extended recombinant bacterial ghost systemW Lubitz, A Witte, F O Eko, et al.
Intensive Care Medicine|April 27, 2026
Risk heterogeneity within hypoinflammatory acute respiratory failure: continuous probabilities identify high-risk patients masked by binary classificationNanditha Venkatesan, Faraaz Ali Shah, William Bain, et al.
Critical Care Explorations|October 16, 2025
Relationship Between Phenotyping and Individualized Absolute Risk Differences in Sepsis: A Secondary Analysis of Two Approaches in Two Multicenter TrialsVictor B Talisa, Sachin P Yende, Derek C Angus, et al.
Critical Care Medicine|October 23, 2024
Heterogeneity in the Effect of Early Goal-Directed Therapy for Septic Shock: A Secondary Analysis of Two Multicenter International TrialsFaraaz Ali Shah, Victor B Talisa, Chung-Chou H Chang, et al.
Intensive Care Medicine|October 3, 2019
Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumabRichard S Hotchkiss, Elizabeth Colston, Sachin Yende, et al.
The New England Journal of Medicine|February 25, 2021
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19, Anthony C Gordon, Paul R Mouncey, et al.
Thorax|May 13, 2025
Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trialLennie Derde, Anthony C Gordon, Paul R Mouncey, et al.
Pageof 27